The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | 5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, summarizes the main findings of the five-year follow-up of the CLL14 study (NCT02242942), which compares the safety and efficacy of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab and chlorambucil in previously untreated patients with chronic lymphocytic leukemia (CLL). Overall, the study showed that patients in the venetoclax arm achieved a durable remission after five years. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
